The global pharma market is set to hit about $1.6 trillion by 2026, according to the Statista Market Outlook, a number that shows just how high the stakes have become. With that kind of money on the table, every move matters. So when a major player like Lonza brings in a new Chief Commercial Officer (CCO), it’s not just a personnel announcement. It makes you wonder how their marketing and client engagement will have to change in a field that’s getting squeezed by regulation on one side and the demand for new drugs on the other.
Key Takeaways
- Lonza’s new CCO is going to push for integrated digital platforms to manage client relationships, getting away from old-school sales tactics and toward something more built on data.
- We’ll see a big emphasis on personalized content. This means using AI to send the right message to the right biopharma partner based on their specific drug pipeline.
- The CCO will probably start tying marketing value directly to client success, shifting to an outcomes-based model where Lonza’s performance is measured by its impact on drug development and manufacturing.
- Don’t be surprised if sustainability and ethical supply chains become a central part of Lonza’s brand story, as the new CCO makes it a core marketing message.
28% of Pharma Marketing Budgets Allocated to Digital Channels in 2026
Digital has completely taken over pharma marketing. By 2026, eMarketer forecasts that 28% of all marketing money in this industry will go to digital channels. And we’re talking about more than just some banner ads or SEO. This budget funds complex content marketing, carefully targeted social media that stays within regulatory lines, and interactive digital portals for partners and researchers. Anyone taking the CCO job at Lonza has to be a digital native. Their job won’t be to just approve a few digital projects. They’ll need to weave digital thinking into every single client touchpoint, from the first email to managing a multi-year manufacturing contract.
From what I’ve seen, the CCO’s first big job won’t be about getting more budget for digital, but about making the current spend actually work. So many pharma companies have disconnected digital efforts, R&D’s content team doesn’t talk to the commercial sales team, and nobody shares data. The new CCO has to smash those silos. They need to build a single, coherent digital presence that uses a common data backbone, which probably means a heavy investment in a solid CRM like Salesforce that can actually give them a 360-degree view of a client’s interactions. This also requires a content team that can move fast, changing messaging as soon as the market or regulators give them a reason to.
Only 15% of Pharma Marketers Feel “Very Confident” in Their Data Analytics Capabilities
Even with all the money flooding into digital, the teams running the show are flying blind. A late 2025 HubSpot survey found that only 15% of pharma marketers feel “very confident” in their data analytics skills. That’s a terrifying number for a high-science company like Lonza. The new CCO has to fix this data problem immediately. Gut-feel marketing is over. Modern pharma marketing is all about evidence, requiring the skill to dig through complicated data to find new clients, figure out what they need, and prove that a campaign actually worked.
This lack of confidence usually comes down to not having the right tools or a clear strategy for using data. The CCO’s job description will almost certainly involve building a central analytics team or, at the very least, getting the marketing department trained on modern analytics platforms. The goal is to get past vanity metrics like page views. It’s about knowing what content actually helps a scientist solve a problem, which channels are bringing in qualified leads, and what marketing activities are really driving business for Lonza’s partners. Without that analytical muscle, all these digital campaigns are just costly science projects. I’d go further and say the CCO has to build a data-first culture, pushing the team toward predictive analytics so they can figure out what clients need before the client even calls.
72% of Biopharma Companies Prioritize “Partnership Value” Over Price in Vendor Selection
It turns out price isn’t everything. A Nielsen industry report just showed that 72% of biopharma companies care more about “partnership value” than cost when they pick a vendor for manufacturing or development. That completely upends the old B2B playbook where the lowest bid wins. For Lonza’s new CCO, this 72% figure is a mandate: build real relationships and prove you’re aligned with your client’s long-term goals. The marketing job shifts from just selling capacity on a manufacturing line to showing how Lonza can become a core part of a client’s own R&D and production team.
This changes everything for the marketing team. They have to stop acting like salespeople and start acting like consultants. Lonza’s marketing needs to prove its scientific brainpower and its deep experience with the FDA and other regulators. That means producing content that actually solves problems, think detailed case studies and technical white papers that demonstrate how they’ve handled a difficult molecule or process before. The CCO has to make sure the marketers have more than just marketing degrees. They need to genuinely understand the entire drug development process and what keeps their clients up at night. Frankly, this is the point. It’s about selling a solution to a client’s multi-million dollar problem, and too many marketing departments are still just pushing a list of their services.
ESG Initiatives Influence 45% of Supplier Decisions in Pharma
ESG isn’t a footnote anymore. It’s a major factor in who gets the contract. According to IAB, Environmental, Social, and Governance initiatives now drive 45% of supplier decisions in pharma. That’s a huge change in how a company like Lonza needs to pitch itself. The new CCO’s job will be to weave Lonza’s sustainability record and ethical standards into every part of its marketing. And this has to be real, verifiable commitment and total transparency, because clients will see right through any greenwashing.
In practice, this means Lonza’s marketing materials need to feature its work in sustainable manufacturing and responsible waste handling. The content should point to specific certifications and internal policies that prove a real ESG commitment. It’s also about giving clients a clear view into the supply chain. A potential partner wants to be able to prove to their own board and to regulators that every part of their drug’s journey meets high ethical standards. The CCO will need to push for tools that let clients trace raw materials and audit manufacturing processes for ethical compliance. In a world where both regulators and the public are watching, this kind of transparency is a massive competitive advantage. Ignoring ESG in your marketing now is just bad business, plain and simple.
Lonza’s new CCO hire is a sign of the times for the whole biopharma industry. This person is walking into a job where success depends entirely on mastering four things: digital fluency, an obsession with data, building true client partnerships, and having a provable ESG story. These are the table stakes now. How this new leader chooses to communicate Lonza’s scientific expertise and manufacturing quality will be fascinating to watch, because it will set a new standard for a marketing discipline that has to be more analytical and accountable than ever.
Which digital marketing channels actually work for biopharma?
You have to go where the scientists are. That means channels like scientific publication platforms, very specific uses of LinkedIn for networking with researchers, and secure client portals are far more effective than broad advertising. Getting your content syndicated in specialized industry news and participating in virtual scientific conferences also generate the kind of high-quality engagement you need.
What does marketing “partnership value” look like in practice?
It’s all about showing, not telling. Lonza needs to produce detailed case studies of successful projects, publish white papers on tough biopharma problems, and make its top scientists available for webinars and one-on-one consultations. All their messaging should hammer home the idea of co-development and being a long-term partner, not just a vendor for one project.
How will the new CCO actually use AI in marketing?
AI is going to be the engine for a lot of this. It’ll be used for the heavy lifting in data analytics, for personalizing content for different types of clients, and for tweaking campaigns on the fly to improve performance. AI tools are also great for market intelligence, helping the team spot new scientific trends or client needs faster than the competition.
For a company like Lonza, what’s in a good ESG marketing message?
A strong ESG message for a CDMO has to be backed by proof. It should talk about specific sustainable manufacturing methods, show responsible material sourcing, and detail ethical labor practices throughout the supply chain. Any contributions to community health are also good to mention. The absolute key is transparency: you need public reports and verifiable certifications to make the message stick.
How do you do digital marketing in pharma without getting in trouble with regulators?
Regulatory compliance is everything in 2026 pharma marketing. It puts tight restrictions on any claims you make, how you handle data privacy, and even who you can target with ads. Every piece of digital content has to follow strict guidelines from the FDA, EMA, or other bodies, which means you need a rock-solid legal review process and probably specialized software just to manage content approval and make sure nothing unapproved ever sees the light of day.
